Cangene Corporation - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Cangene Corporation. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Cangene Corporation. The Group's principal activities are to develop and distribute hyperimmune products and recombinant biopharmaceuticals. Hyperimmune products are specialty antibody preparations made from plasma products. Recombinant protein products are therapeutic proteins made by introducing a particular gene into a host organism, which in turn produces the protein of interest. The Group operates in two segments namely Contract R&D and Manufacturing and Biopharmaceutical Operations. Biopharmaceutical Operations include in-house licensed product sales and royalties and related party research and development. Contract R&D and Manufacturing provides products and services to third party clients. The Group develops and supplies antibody products that may aid in the fight against challenging infectious diseases such as smallpox, Ebola, anthrax, West Nile and hepatitis. The Group markets its products in Canada, the United States and other foreign countries.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report